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Running title:  Research in public health emergencies 
 
Key Points:  To obtain definitive information about the effects of treatments and 
vaccines, even in public health emergencies, randomized clinical trials are 
essential.  Such trials are ethical and feasible with efforts to engage and 
collaborate with the affected communities. 
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ABSTRACT 
 
Randomized clinical trials are the most reliable approaches to evaluating the 
effects of new treatments and vaccines.  During the 2014-15 West African Ebola 
epidemic, many argued that such trials were neither ethical nor feasible in an 
environment of limited health infrastructure and severe disease with a high 
fatality rate.  Consensus among the numerous organizations providing help to the 
affected areas was never achieved, resulting in fragmented collaboration, delayed 
study initiation, and ultimately failure to provide definitive evidence on the 
efficacy of treatments and vaccines.  Randomized trials were in fact approved by 
local ethics boards and initiated, demonstrating that randomized trials, even in 
such difficult circumstances, are feasible.  Improved planning and collaboration 
among research and humanitarian organizations, and affected communities, in 
the interepidemic periods are needed to ensure that questions regarding the 
efficacy of vaccines and treatments can be definitively answered during future 
public health emergencies.  
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The West African Ebola outbreak of 2014-2015 was unprecedented.  As the first 
multi-country Ebola epidemic, it affected more individuals and caused more 
deaths than all previous Ebola outbreaks combined. Unfortunately, awareness of 
its scope was slow to develop, delaying the initiation of clinical trials. None of the 
completed therapeutic trials demonstrated efficacy (although the results of one 
were suggestive); one of four vaccine trials produced results strongly suggestive 
of protective efficacy but with interpretive difficulties.  To better plan for trials in 
a future outbreak – whether Ebola or another emerging infection –the US 
National Academies of Sciences, Engineering, and Medicine convened a 
committee to systematically review the studies conducted during the outbreak 
and to make recommendations for the future. The report, released in April 2017 
[1], evaluated the study designs proposed/employed [2-9] and considered how to 
improve the quality of future research.  Here we summarize the report’s 
conclusions about study designs.  
 
Randomized clinical trials (RCTs) are generally recognized as the optimal way to 
evaluate new therapeutic and preventive interventions [10-14]. However, in 
situations involving serious diseases without satisfactory treatment this approach 
has been questioned [15-19].  Although a handful of treatments have been shown 
effective in small, uncontrolled studies, such as platinum for treatment of 
testicular cancer [20], this is exceedingly rare.  Most effective interventions 
provide modest to moderate improvements, which cannot be reliably identified in 
uncontrolled studies. The RCT’s two primary attributes—use of a concurrent 
control group and the random assignment of treatments—are critical to drawing 
valid conclusions about treatment effects.   
Concurrent Control Group.  If individuals with a particular disease or condition 
had uniform outcomes there would be no need for control groups. But this is 
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rarely the case—even diseases with known poor prognosis typically have variable 
courses.  In addition, emergence of new techniques allowing earlier diagnosis, or, 
as observed during the West Africa Ebola outbreak, the introduction of improved 
supportive care over time, make the historical experience for evaluating new 
treatments problematic.  
Random Treatment Assignment.   
Individuals who agree to participate in a clinical trial may differ from others with 
the same diagnosis in ways that affect prognosis.  Even when adjusting for factors 
known to affect study outcomes, nonrandomized studies can be misleading due 
to differences in unmeasured or unknown factors.  Countless examples of 
purported treatment effects emerging from observational data have been 
definitively refuted in subsequent RCTs.  [21-24].    
Clinical Trial Designs during the 2014-15 Ebola Outbreak 
At the outset of the Ebola epidemic several experimental drugs and vaccines were 
in very early stages of development and none had yet been studied in humans.   
Unfortunately, consensus regarding priority interventions and trial designs was 
difficult to achieve.  A particular area of debate was whether an RCT was ethical in 
the face of such a public health emergency [19, 25].  Some argued that 
randomization to a placebo control (in addition to all available supportive care) 
would be unethical given the expected high mortality, and presumed the affected 
communities would reject such a design. These concerns led several investigative 
teams to initiate uncontrolled trials of experimental treatments, hoping to 
observe a survival rate high enough to establish efficacy based on comparison 
with historical estimates [26-28].  Others suggested initial uncontrolled trials of 
investigational agents rapidly followed by RCTs for any agent found promising but 
not definitively effective [3].  This approach was applied to just one agent, which 
did not pass the first stage before the epidemic waned [29].    A “platform” design 
was also proposed, randomizing individuals among several different treatments 
and increasing the proportion randomized to treatments that appeared to be 
more effective as the trial progressed [5]; however, the epidemic was brought 
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under control before it could be implemented.    Only one RCT, comparing ZMapp 
to placebo with everyone receiving optimized supportive care, was initiated [30].   
Ultimately the uncontrolled therapeutic trials did not demonstrate the extremely 
large effects required for credible conclusions, and the single RCT evaluating 
ZMapp did not enroll enough patients before the epidemic waned to definitively 
assess benefit. The observed mortality of 37% in the control group was 
substantially lower than the historical rates, demonstrating the difficulty in 
interpreting uncontrolled data.   Had the mortality been as low as 37% in the 
single-arm trials, the products studied would have been viewed as extremely 
promising, as expected mortality was at least 50%.   
In the case of vaccine trials, randomization was less controversial because the 
individuals involved were not currently ill. Several RCTs were initiated [31-34] but 
the only study able to evaluate efficacy used an innovative “ring” strategy in 
which clusters were defined around observed cases, and then randomized to 
immediate or delayed vaccination [31].  This approach defined clusters at 
elevated risk of infection so that despite the waning of the epidemic enough cases 
were observed to permit meaningful efficacy analysis. A statistically significant 
estimate of 100% protection was obtained when individuals in the “immediate” 
clusters who actually received vaccine (approximately two-thirds of this 
randomized cohort) were compared to all individuals in the clusters randomized 
to “delayed” vaccination.  However, this analysis violates the intention-to-treat 
(ITT) principle, which requires inclusion of all individuals randomized to both arms 
whether or not they received the experimental treatment [35].  The ITT results 
(included as an additional analysis in the final report) yielded a lower estimate of 
vaccine efficacy of 65%, which did not reach statistical significance.  This is not a 
minor technicality—those randomized to be vaccinated but were not could be 
different from those who were vaccinated in ways that influenced the likelihood 
of infection [36].  Further, the trial was not masked to control potential biases in 
identifying cases.    
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These findings present major challenges for regulators, product manufacturers 
and research organizations.  Without definitive evidence of efficacy, will products 
be approved?  Will manufacturers ramp up production of the promising products 
whether or not regulatory approval is granted, in anticipation of “compassionate 
use” in a future outbreak?  Will trial organizers plan further studies using these 
products as controls instead of using placebo controls?   
Urgency does not Override the Need for Reliable Results 
It is understandable that in a context with no known effective therapies, those 
treating the sick would want to use any accessible and potentially active 
treatment [37].  But conducting human research in a manner that does not 
conform to scientific standards and is thus unlikely to yield actionable findings is 
itself ethically questionable [38].  If drugs were approved based on promising 
early uncontrolled results, the outcome could be a plethora of new available 
treatments; individuals and physicians in desperate situations would have 
multiple drugs to choose from but no reliable information about their effects.  No 
group has understood this dilemma better than the AIDS activists in the late 
1980s, who very quickly became strong advocates for rigorous study designs to 
evaluate new treatments for HIV [39].   
Similar considerations apply to vaccines.  Public health officials dealing with future 
outbreaks will face an inevitable and difficult trade-off between obtaining efficacy 
data as rapidly as possible, and obtaining the long term observations needed to 
fully assess product safety and durability of protection. 
Summary:  Promoting further Conversation and Consensus.  
The scientific output from the clinical trials in West Africa has been characterized 
as “thin” [40]. It took too long for trials to be planned, vetted and initiated and, as 
most of the trials were neither randomized nor adequately controlled, results 
could not in the end support conclusions about safety or efficacy. This experience 
should motivate investigators to plan for the inevitable future epidemics during 
the interepidemic periods and to drive consensus about trial design and conduct 
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among the various research and humanitarian organizations and local 
communities before the next outbreak, whether of Ebola or another pathogen 
[41, 42]. Otherwise, we may well repeat the disappointing outcomes of the recent 
Ebola experience.   
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